BIONDVAX PHARMACEUTICALS LTDICAN DEPOSITARY SHARES

Depository Receipt · US09073Q1058 · BVXV · A14TFZ (XNCM)

No Price

n/a

Company Profile for BIONDVAX PHARMACEUTICALS LTDICAN DEPOSITARY SHARES Depository Receipt

BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Get up to date insights from finAgent about BIONDVAX PHARMACEUTICALS LTDICAN DEPOSITARY SHARES

Company Data

Name BIONDVAX PHARMACEUTICALS LTDICAN DEPOSITARY SHARES

Company BiondVax Pharmaceuticals Ltd.

Symbol BVXV

Website https://www.biondvax.com

Primary Exchange

NASDAQ CAPITAL MARKET

WKN A14TFZ

ISIN US09073Q1058

Asset Class Depository Receipt

Sector Healthcare

Industry Biotechnology

CEO Amir Reichman

Country Israel

Currency USD

Employees 0,0 T

Address Jerusalem BioPark Building, Jerusalem

IPO Date 2015-05-12

Stock Splits

Date	Split
25.11.2022	1:10

Ticker Symbols

Name	Symbol
NASDAQ	BVXV

More Shares

Investors who hold BIONDVAX PHARMACEUTICALS LTDICAN DEPOSITARY SHARES also have the following shares in their portfolio:

Mullion Co., Ltd. Share

REP. FSE 16-36 O.A.T. Bond

The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.

Imprint Data Protection Blog Community Feedback Changelog